The province of British Columbia is inviting input from the public about coverage for Maviret® (glecaprevir-pibrentasvir), a drug used to treat hepatitis C in pediatric patients, in two different formulations: Granules for pediatric patients between the ages of 3 and 12. Taken in granule …